3D Global Biotech (ROCO:6808) Total Equity: NT$984.5 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6808 3D Global Biotech Inc ROCO:6808
70 GF Score
Price NT$38.85
GF Value NT$185.91
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is 3D Global Biotech Total Equity?

3D Global Biotech ROCO:6808 -3.00% 70 Total Equity is NT$984.5 Mil as of Dec. 2025. GuruFocus rates ROCO:6808 with a GF Score™ of 70/100 and a GF Value™ of NT$185.91 (Significantly Undervalued). The stock has 4 warning signs investors should review.

3D Global Biotech's total equity for the quarter that ended in Dec. 2025 was NT$984.5 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

3D Global Biotech Total Equity Historical Data

* Premium members only.

The historical data trend for 3D Global Biotech's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

3D Global Biotech Total Equity Chart

3D Global Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only 389.71 340.60 293.47 904.69 984.53

3D Global Biotech Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 293.47 457.04 904.69 905.47 984.53
ROCO:6808
70GF Score
3D Global Biotech Inc ROCO:6808
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

3D Global Biotech Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

3D Global Biotech's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1090.647-106.119
=984.5

3D Global Biotech's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1090.647-106.119
=984.5

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of NT$984.5 Mil mean?
3D Global Biotech (ROCO:6808) has a Total Equity of NT$984.5 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for 3D Global Biotech and its competitors.
Is 3D Global Biotech's Total Equity too high?
3D Global Biotech's current Total Equity is NT$984.5 Mil. Overall, 3D Global Biotech has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does 3D Global Biotech's Total Equity compare to VRTX and REGN?
3D Global Biotech's Total Equity of NT$984.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for 3D Global Biotech and its competitors. 3D Global Biotech's current Total Equity is NT$984.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3D Global Biotech stock overvalued right now?
Based on GuruFocus' analysis, 3D Global Biotech (ROCO:6808) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$185.91, compared to a current price of NT$38.85 — trading 79.1% below its estimated fair value. The current Total Equity is NT$984.5 Mil. 3D Global Biotech's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For 3D Global Biotech (ROCO:6808), the current Total Equity is NT$984.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 3D Global Biotech (ROCO:6808) Overvalued in 2026?

Based on GuruFocus' analysis, 3D Global Biotech stock appears to be undervalued. The current stock price of NT$38.85 is trading 79.1% below its estimated GF Value™ of NT$185.91. GuruFocus considers 3D Global Biotech to be Significantly Undervalued.

Key valuation signals for ROCO:6808:

  • Total Equity: NT$984.5 Mil
  • GF Value™: NT$185.91 vs. price of NT$38.85 (79.1% below fair value)
  • GF Score™: 70/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6808 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

3D Global Biotech Business Description

Address No.99, Section 1, Xintai 5th Road, 21st Floor -3, Xizhi District, New Taipei, TWN, 221
3D Global Biotech Inc is engaged in the research and development of high-end medical equipment and biological 3D printing technology and the sale of medical Materials and other related products.
70GF Score

Get the complete analysis for ROCO:6808

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$38.85
Price
NT$185.91
GF Value